Published • loading... • Updated
Canada Expands Ocrevus Approval to Children with Relapsing MS
Summary by Multiple Sclerosis News Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Canada expands Ocrevus approval to children with relapsing MS
Children and teenagers in Canada with relapsing-remitting multiple sclerosis (RRMS) now have a second treatment option following Health Canada’s approval of the infusion therapy Ocrevus (ocrelizumab). The regulatory decision extends the use of Ocrevus to patients 10 and older. Previously authorized in Canada only for adults, Ocrevus joins daily oral Gilenya (fingolimod) as the only […]
The intravenous preparation of Ocrevus (Ocrevus IV) responds to a crying need for paediatric multiple sclerosis (MS) as a therapeutic option
·Montreal, Canada
Read Full ArticleCoverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
